Artificial Bone Graft Substitutes for Curettage of Benign and Low-Grade Malignant Bone Tumors: Clinical and Radiological Experience with Cerasorb

Abstract Background Artificial bone graft substitutes (ABGS) for curettage of tumors are becoming increasingly popular. The aim this retrospective analysis was to determine the efficacy ABGS Cerasorb (Curasan-AG, Kleinostheim, Germany), a beta-tricalcium phosphate (beta-TCP), concerning resorption profile, healing, and remodeling after surgery evaluate potential complications. Methods Forty-three patients suffering from benign low-grade malignant were treated with refilling bony cavity using between 2018 2021 included in final analysis. Clinical follow-up exams X-rays two planes performed 6 weeks, 3 months, 1 year surgery. Results After mean period 14.6 radiological consolidation following observed all patients. Total 16.3% patients; other 83.7%, partial. In four patients, whom had tumor distal femur humeral diaphysis, fractures occurred within weeks primary Conclusion conclusion, beta-TCP seems be reliable substitute low complication rates is suitable alternative autologous grafts or allografts. Nonetheless, it shows tendency delayed resorption. Level Evidence III; cohort study.